Aurobindo Pharma's Eugia Unit Gets US FDA OAI Classification

Key Event and Details

The United States Food and Drug Administration (US FDA) inspected Unit-I, a formulation manufacturing facility, of Eugia Pharma Specialities Limited. The facility is located at Kolthur Village, Shameerpet Mandal, Ranga Reddy, 500078, Telangana. The inspection was conducted from February 16, 2026, to February 27, 2026, and concluded with 4 observations.

Regulatory Action and Date of Receipt

The US FDA has determined that the inspection classification for this facility is "official action indicated" (OAI). The company received this communication from the authority on May 23, 2026.

Stated Impact

As per the disclosure, there is no impact on Aurobindo Pharma Limited's financials or operations due to this regulatory action. The impact is stated to be not quantifiable in monetary terms.

Company Commitment and Forward Statement

The company states its commitment to maintaining the highest quality manufacturing standards at all its global facilities. It has committed to keeping the stock exchanges informed of any further developments relating to this matter.

The letter was digitally signed by B. Adi Reddy, Company Secretary, on May 24, 2026, at 17:25:43 IST.

#Tags: #AurobindoPharma #EugiaPharma #USFDA #SEBIDisclosure #RegulatoryCompliance #Neutral